Global Bacterial Vaginosis Treatment Market, By Treatment (Medication, Others), Dosage Form (Creams, Gel, Pills, Solution/Washes, Injection, Others), Route of Administration (Oral, Vaginal, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The expected CAGR of bacterial vaginosis treatment market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 970 million in 2021, and it would grow upto USD 1862.99 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Sciinov Insights Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Key players operating in the bacterial vaginosis treatment market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- AbbVie Inc. (U.S.)
- Melinta Therapeutics, Inc (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GlaxoSmithKline plc. (U.K.)
- Bayer AG (Germany)
- Lupin (India)
- Mission Pharmacal Company (U.S.)